Studies on the metabolism of benoxinate by human pseudocholinesterase.
The local anesthetic drug benoxinate (oxybuprocaine, Novesine) is hydrolyzed to 3-butoxy-4-aminobenzoic acid. A rapid and simple spectrophotometric method for benoxinate hydrolysis by human plasma was developed. Benoxinate is hydrolyzed enzymatically by an esterase present in the serum. Heat stability characteristics and apparent affinity values of the benoxinate metabolizing enzyme were in the same range compared to benzoylcholine chloride hydrolysis. Apparent Vmax-values differ by a mean factor of about 18 between the hydrolysis of both substrates. Considerable interindividual variability of benoxinate hydrolysis and inhibition of the enzymatic reaction by dibucaine and sodium fluoride has been observed. Furthermore, enzyme activity with benoxinate as substrate is positively correlated (P less than 0.001) with benzoylcholine chloride hydrolysis. Therefore, we assume that benoxinate is metabolized by human pseudocholinesterase (PCHE, E.C. 3.1.1.8) and that ocular side effects after benoxinate application may be caused by altered metabolism of this drug, depending on genetically determined variants of pseudocholinesterase.
D000328:Adult; D001588:Benzoylcholine / Q000378:metabolism; D002091:Butyrylcholinesterase / Q000097:blood / Q000494:pharmacology*; D002800:Cholinesterase Inhibitors; D002802:Cholinesterases / Q000494:pharmacology*; D003992:Dibucaine / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D011343:Procaine / Q000031:analogs & derivatives* / Q000378:metabolism; D012969:Sodium Fluoride / Q000494:pharmacology
D002800:Cholinesterase Inhibitors; D001588:Benzoylcholine; D011343:Procaine; D012969:Sodium Fluoride; C005298:benoxinate; D002091:Butyrylcholinesterase; D002802:Cholinesterases; D003992:Dibucaine